The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ctDNA tumor fraction (TF) to predict response to nivolumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): An analysis of the multicentric phase 2 TOPNIVO trial.
 
Filippo Dall'Olio
No Relationships to Disclose
 
Wael Zrafi
No Relationships to Disclose
 
Adsaya Rathakrishnan
No Relationships to Disclose
 
Maeva Moreau
No Relationships to Disclose
 
Rebecca Ibrahim
No Relationships to Disclose
 
Matthieu Texier
No Relationships to Disclose
 
Adrien Laville
No Relationships to Disclose
 
Damien Vasseur
No Relationships to Disclose
 
Patrick Saulnier
No Relationships to Disclose
 
Amaury Daste
Consulting or Advisory Role - BMS; Merck; Merus; MSD
Travel, Accommodations, Expenses - BMS; Merck
 
Karim Benihoud
No Relationships to Disclose
 
Pierre Busson
No Relationships to Disclose
 
Ivan Bieche
No Relationships to Disclose
 
Clemence Toullec
No Relationships to Disclose
 
Mariana Iacob
No Relationships to Disclose
 
Roger Sun
No Relationships to Disclose
 
Anne Auperin
No Relationships to Disclose
 
Laure Monard
No Relationships to Disclose
 
Ludovic Lacroix
No Relationships to Disclose
 
Caroline Even
Consulting or Advisory Role - Bristol-Myers Squibb; Fstar Therapeutics (Inst); GlaxoSmithKline (Inst); Innate Pharma; Merck Serono; Merus (Inst); MSD Oncology; Novartis (Inst)
Travel, Accommodations, Expenses - Merck Serono; Merck Serono; MSD Oncology